Doxorubicin-Induced Cardiomyopathy Overview

Save information for later
Sign Up

Learn About Doxorubicin-Induced Cardiomyopathy

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Doxorubicin-Induced Cardiomyopathy Local Doctors?
Elite in Doxorubicin-Induced Cardiomyopathy
Ashim K. Bagchi
Elite in Doxorubicin-Induced Cardiomyopathy
Ashim K. Bagchi
St. Boniface Hospital Albrechtsen Research Centre, 
Winnipeg, MB, CA 

Ashim Bagchi practices in Winnipeg, Canada. Bagchi and is rated as an Elite expert by MediFind in the treatment of Doxorubicin-Induced Cardiomyopathy. His top areas of expertise are Doxorubicin-Induced Cardiomyopathy, Cardiomyopathy Due to Anthracyclines, Cardiomyopathy, and Necrosis.

Elite in Doxorubicin-Induced Cardiomyopathy
Pawan K. Singal
Elite in Doxorubicin-Induced Cardiomyopathy
Pawan K. Singal
St. Boniface Hospital Albrechtsen Research Centre, Rm. 3042, 351 Taché Avenue, 
Winnipeg, MB, CA 

Pawan Singal practices in Winnipeg, Canada. Singal and is rated as an Elite expert by MediFind in the treatment of Doxorubicin-Induced Cardiomyopathy. His top areas of expertise are Doxorubicin-Induced Cardiomyopathy, Cardiomyopathy Due to Anthracyclines, Cardiomyopathy, and Heart Failure.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Doxorubicin-Induced Cardiomyopathy
Nicola Maurea
Elite in Doxorubicin-Induced Cardiomyopathy
Nicola Maurea
Naples, IT 

Nicola Maurea practices in Naples, Italy. Maurea and is rated as an Elite expert by MediFind in the treatment of Doxorubicin-Induced Cardiomyopathy. Her top areas of expertise are Cardiomyopathy Due to Anthracyclines, Doxorubicin-Induced Cardiomyopathy, Heart Failure, and Breast Cancer.

View All Doctors
What are the latest Doxorubicin-Induced Cardiomyopathy Clinical Trials?
ANTICIPATE: Prevention of ANThracycline-Induced Cardiac Dysfunction by Dexrazoxane In PATients With diffusE Large B-cell Lymphoma: a Phase III National Multicenter Prospective Randomized Open-label Trial
ANTICIPATE: Prevention of ANThracycline-Induced Cardiac Dysfunction by Dexrazoxane In PATients With diffusE Large B-cell Lymphoma: a Phase III National Multicenter Prospective Randomized Open-label Trial
Enrollment Status: Recruiting
Publish Date: September 19, 2024
Intervention Type: Drug
Study Phase: Phase 3

Summary: Patients treated for DLBCL are at high risk of developing AICD. This adverse event is characterized by irreversible damage to the heart muscle with a loss of cardiomyocytes and subsequent decline in cardiac pumping capacity. Thereby patients treated for this malignancy are at double the risk of developing symptomatic heart failure / cardiomyopathy when compared to the general population. This corr...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients
Enrollment Status: Recruiting
Publish Date: October 23, 2023
Intervention Type: Drug
Study Phase: Phase 2

Summary: Purpose：1. Preliminary evaluation of the preventive effect of DH001 on doxorubicin-induced cardiotoxicity in cancer patients 2.To explore appropriate dosages to provide basis for dosages in subsequent confirmatory studies 3.To evaluate the effect of DH001 on the efficacy of doxorubicin treatment in cancer patients 4.To evaluate the safety of DH001 in cancer patients treated with doxorubicin

View All Clinical Trials